Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA)

Drug (Brand / Generic)

Spinraza / nusinersen

Company / Licensee

Ionis Pharmaceuticals / Biogen

Therapy Class

Anti-sense therapy

Product Description

Anti-sense oligonucleotide

Current Indication

Spinal muscular atrophy

Market Sector

Central nervous system

Development Status

Approved in the US, marketing approval under review in Europe, Japan, Canada, and Australia
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top